The data for these analyses were made available to the authors by third-party license from Truven MarketScan, a commercial data provider in the US, and BMS (who have a license for analysis of the Truven MarketScan data). As such, the authors cannot provide the raw data themselves. Other researchers could access the data by purchase through Truven MarketScan; and the inclusion criteria specified in the Methods section would allow them to identify the same cohort of patients the authors used for these analyses. Interested individuals may see <http://truvenhealth.com/markets/life-sciences/products/data-tools/marketscan-databases> for more information on accessing Truven MarketScan data. The authors confirm that no authors had special privileges to access data from Truven MarketScan via third-party license, and that other researchers would be able to access the data in the same manner as the authors.

Introduction {#sec001}
============

While warfarin is highly effective for preventing stroke in patients with atrial fibrillation (AF), there is significant inter- and intra-patient variability in dose requirements, thus necessitating regular anticoagulation monitoring. Warfarin is also associated with many diet and drug interactions and can be associated with a significant rate of major bleeding, particularly intracranial hemorrhage \[[@pone.0195950.ref001],[@pone.0195950.ref002]\]. Given these difficulties, many at-risk AF patients do not receive warfarin or receive an inadequate dose, and often discontinue therapy \[[@pone.0195950.ref001],[@pone.0195950.ref002]\]. As a result, approximately 30--50% of patients have been undertreated with either suboptimal warfarin treatment, aspirin, or no anticoagulation \[[@pone.0195950.ref003]\]. In recent years, 4 non-Vitamin K antagonist oral anticoagulants (NOACs), including dabigatran, rivaroxaban, apixaban, and edoxaban, have been approved in the United States for stroke prevention in NVAF patients. The NOACs have advantages over warfarin in that there is no need for regular International Normalized Ratio (INR) monitoring, and there are fewer drug and food interactions. In clinical trials assessing warfarin, dabigatran, rivaroxaban, apixaban, and edoxaban, all have been shown to be safe and effective \[[@pone.0195950.ref004]--[@pone.0195950.ref007]\]. Among all NOACs approved for non-valvular AF (NVAF), apixaban is the only drug that has shown, in its respective clinical trial(s), to have a significantly lower discontinuation rate than warfarin (or aspirin) possibly due to its significantly better safety and tolerability profile \[[@pone.0195950.ref006],[@pone.0195950.ref008],[@pone.0195950.ref009]\]. Due to the moderate half-life of NOACs, it is important for patients to continue to take medications daily, as indicated. For both warfarin and NOACs, drug discontinuation and missing doses (ie, lower adherence) may expose AF patients to an increased risk of stroke. Consequently, studies of discontinuation and adherence associated with NOACs are important in understanding treatment patterns and associated gaps \[[@pone.0195950.ref010],[@pone.0195950.ref011],[@pone.0195950.ref012]\]. It would be important to investigate discontinuation rates and time to discontinuation associated with various NOACs to understand the ability of patients to continue long-term NOAC use in real-world settings. The objective of this study was to describe the 'real-world' discontinuation rates and compare the risk of drug discontinuation among patients initiating apixaban, dabigatran, rivaroxaban, and warfarin. For the purposes of this analysis, there were insufficient real-world data available for edoxaban in the United States.

Methods {#sec002}
=======

A retrospective cohort study was conducted using the Truven MarketScan^®^ Commercial Claims & Encounters and Medicare Supplemental & Coordination of Benefits database (January 2012 through December 2014) to evaluate the discontinuation rates among AF patients who initiated apixaban, warfarin, dabigatran, or rivaroxaban treatment \[[@pone.0195950.ref013]\]. The database includes health insurance claims for over 60 million employees, spouses, retirees, and their dependents, enrolled in employer-sponsored commercial and Medicare advantage plans. The geographical distribution is approximately the same as the US population distribution. The database includes fully-integrated health information, including inpatient and outpatient health care resource utilization and detailed drug information. The pharmaceutical claims file includes complete records of prescriptions, including mail-order or card program prescription drug claims \[[@pone.0195950.ref013]\].

NVAF patients aged ≥18 years (identified based on presence of at least 1 claim for a primary or secondary diagnosis of AF in the inpatient or outpatient setting using ICD-9-CM code 427.31 or 472.32) with a 1-year baseline period with continuous health plan enrollment were included if they were newly prescribed oral anticoagulants from January 1, 2013 through December 31, 2014 \[[@pone.0195950.ref014]\]. The ICD-9 codes have been validated for identifying AF patients with a median positive predictive value of 89% \[[@pone.0195950.ref014]\]. In other words, a contemporary cohort of NOAC and warfarin initiators without prior oral anticoagulant treatment during the 1-year baseline period was selected for this study. The index drug was defined as the first anticoagulation treatment prescribed to patients included in the study. The index date was defined as the first index drug prescription date, after NVAF diagnosis. The index date is depicted in [Fig 1](#pone.0195950.g001){ref-type="fig"}.

![Study period depiction.\
Study period for patients initiating apixaban, dabigatran, rivaroxaban, and warfarin. AF: atrial fibrillation.](pone.0195950.g001){#pone.0195950.g001}

Patients with claims including ICD-9-CM diagnosis codes for transient AF (pericarditis, hyperthyroidism, thyrotoxicity), valvular heart disease, venous thromboembolism, cardiac surgery, or pregnancy during the baseline period (any time prior to or on the index date) were excluded ([Fig 2](#pone.0195950.g002){ref-type="fig"}; [S1 Table](#pone.0195950.s004){ref-type="supplementary-material"}).

![Patient selection criteria.\
Study population flow chart with inclusion and exclusion criteria used to select 45,361 patients. NOAC: non-vitamin K antagonist oral anticoagulant; VTE: venous thromboembolism.](pone.0195950.g002){#pone.0195950.g002}

Discontinuation was defined as a gap in therapy when a subsequent prescription for the index treatment occurred \>30 days, plus the days supply of the previous prescription \[[@pone.0195950.ref012]\]. Patients who did not discontinue treatment were followed until the date of a switch to another anticoagulant, end of the study period, inpatient death, or interruption in continuous health plan enrollment, whichever occurred earliest. A sensitivity analysis was completed by changing the discontinuation gap to 60 days and 90 days.

A second sensitivity analysis was also performed. Due to varying mean length of follow-up across treatment cohorts, only patients who had at least 100 days of follow-up were included, in order to assess the robustness of the estimated risk of discontinuation.

In the study population, categorical and continuous variables were compared across treatments using the Pearson chi-square test and the Wilcoxon rank-sum test, respectively. The proportions of patients discontinuing therapy during the study follow-up period were computed as the number of patients who discontinued treatment divided by the total number of patients initiating the treatment within the study period. The cumulative incidence of discontinuation was presented using Kaplan--Meier curves. A Cox proportional hazards model was used to estimate the hazard ratios (HRs) of discontinuation for each drug compared to apixaban, adjusted for a pre-specified set of baseline demographic and clinical factors including age, sex, embolic or primary ischemic stroke, dyspepsia or stomach discomfort, congestive heart failure, coronary artery disease, diabetes mellitus, hypertension, renal disease, myocardial infarction, history of stroke, or transient ischemic attack, and history of bleeding ([S1 Table](#pone.0195950.s004){ref-type="supplementary-material"}).

As warfarin is the standard of care, we have analyzed and presented the primary results using warfarin as a reference comparator. Lower discontinuation rates were observed for NOACs in real-world studies and clinical trials; therefore, we also analyzed apixaban as a reference cohort to understand the discontinuation risk associated with NOACs and warfarin in the real-word setting. All analyses were performed with SAS System version 9.2. An *a priori* significance level of 0.05 was used for the purposes of these analyses.

Results {#sec003}
=======

Among 45,361 patients, 15,461 (34.1%) initiated warfarin treatment with a mean (SD) follow-up of 164 (±162) days; 7,438 (16.4%) initiated apixaban with a mean follow-up of 148 (±138) days; 4,661 (10.3%) initiated dabigatran with a mean follow-up of 177 (±179) days; and 17,801 (39.2%) patients initiated rivaroxaban with a mean follow-up of 176 (±171) days ([Table 1](#pone.0195950.t001){ref-type="table"}). Approximately 60% of patients in each treatment group were male. The mean age of warfarin, apixaban, dabigatran, and rivaroxaban patients was 71.7±12.0, 68.5±12.4, 66.5±12.4, and 67.1±12.3 years, respectively. Patients initiating warfarin were older and were at higher risk in terms of the CHA~2~DS~2~-VASc score (3.2±1.7) and had higher mean Charlson comorbidity index (CCI) scores of 2.3±2.3 ([Table 1](#pone.0195950.t001){ref-type="table"}).

10.1371/journal.pone.0195950.t001

###### Baseline patient characteristics and treatment follow-up period.

![](pone.0195950.t001){#pone.0195950.t001g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                Apixaban (n = 7,438)   Dabigatran (n = 4,661)   Rivaroxaban (n = 17,801)   Warfarin (n = 15,461)                              
  ------------------------------------------------------------- ---------------------- ------------------------ -------------------------- ----------------------- --------- ------ --------- ------
                                                                N/Mean                 %/SD                     N/Mean                     %/SD                    N/Mean    %/SD   N/Mean    %/SD

  Age                                                           68.5                   12.4                     66.5                       12.4                    67.1      12.3   71.7      12.1

   18--64                                                       3111                   41.8                     2234                       47.9                    8245      46.3   4845      31.3

   65--74                                                       1805                   24.23                    1096                       23.5                    4208      23.6   3595      23.3

   75+                                                          2522                   33.9                     1331                       28.6                    5348      30.0   7021      45.4

  Sex                                                                                                                                                                                         

   Male                                                         4566                   61.4                     3028                       65.0                    11310     63.5   9254      59.9

   Female                                                       2872                   38.6                     1633                       35.0                    6491      36.5   6207      40.2

  Embolic or Primary\                                           523                    7.0                      259                        5.6                     1056      5.9    1551      10.0
  Ischemic Stroke                                                                                                                                                                             

  Dyspepsia or Stomach Discomfort                               1082                   14.6                     564                        12.1                    2548      14.3   2470      16.0

  Congestive Heart Failure                                      1454                   19.6                     873                        18.7                    3293      18.5   4021      26.0

  Coronary Artery Disease                                       2410                   32.4                     1283                       27.5                    5112      28.7   5305      34.3

  Diabetes                                                      2108                   28.3                     1269                       27.2                    4802      27.0   4987      32.3

  Hypertension                                                  5585                   75.1                     3253                       69.8                    12690     71.3   11334     73.3

  Renal Disease                                                 638                    8.6                      333                        7.1                     1398      7.9    2242      14.5

  Myocardial Infarction                                         469                    6.3                      251                        5.4                     1089      6.1    1378      8.9

  History of Stroke or TIA                                      754                    10.1                     413                        8.9                     1574      8.8    2061      13.3

  History of Bleeding                                           1012                   13.6                     536                        11.5                    2421      13.6   2800      18.1

  CHA~2~DS~2~-VASc Score[\*](#t001fn002){ref-type="table-fn"}   2.8                    1.6                      2.6                        1.7                     2.6       1.7    3.2       1.7

  0                                                             514                    6.9                      485                        10.4                    1650      9.3    766       5.0

  1                                                             1222                   16.4                     908                        19.5                    3401      19.1   1809      11.7

  2                                                             1644                   22.1                     1027                       22.0                    3884      21.8   2750      17.8

  ≥3                                                            4058                   54.6                     2241                       48.1                    8866      49.8   10136     65.6

  Charlson Comorbidity Index Score                              1.8                    2.0                      1.6                        1.9                     1.7       2.0    2.3       2.3

  0                                                             2244                   30.2                     1631                       35.0                    6117      34.4   3741      24.2

  1                                                             1899                   25.5                     1201                       25.8                    4468      25.1   3434      22.2

  2                                                             1270                   17.1                     729                        15.6                    2721      15.3   2499      16.2

  ≥3                                                            2025                   27.2                     1100                       23.6                    4495      25.3   5787      37.4

  Treatment Follow-up (in days)                                 148                    138                      177                        178                     175       171    164       162

  Median                                                        95                     \-                       100                        \-                      111       \-     101       \-

  IQR                                                           36--215                \-                       30--255                    \-                      35--261   \-     40--233   \-
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SD: Standard Deviation; TIA: Transient Ischemic Attack; IQR: Interquartile Range.

\*The CHA~2~DS~2~-VASc score was calculated as the sum of points associated with each of the following attributes: congestive heart failure (1 point), hypertension (1 point), age ≥75 (2 points), diabetes (1 point), prior stroke or TIA (2 points), vascular disease (1 point), age 65--74 (1 point), female (1 point).

[Fig 3](#pone.0195950.g003){ref-type="fig"} shows the discontinuation rates of all drugs across the study period. The cumulative incidence of discontinuation at one-year was 50.5%, 64.7%, 57.8%, and 71.6% for apixaban, dabigatran, rivaroxaban, and warfarin patients, respectively. When the 60- and 90-day gap was used, the rates of discontinuation were lower but the trend was consistent ([S2 Table](#pone.0195950.s005){ref-type="supplementary-material"}, [S2](#pone.0195950.s002){ref-type="supplementary-material"} and [S3](#pone.0195950.s003){ref-type="supplementary-material"} Figs). Across the four cohorts, around 3--10% of patients switched from index OAC to another OAC during the follow-up period.

![Cumulative incidence of discontinuation among newly anticoagulated non-valvular atrial fibrillation patients.\
(Upper panel) Cumulative incidence of discontinuation during the follow-up period. The unadjusted cumulative incidence of discontinuation was lower among patients initiated on apixaban compared to patients inititated on other oral anticoagulants. (Lower panel) The number of patients at risk for discontinuation at varying points during the follow-up.](pone.0195950.g003){#pone.0195950.g003}

When *compared to warfarin*, patients who initiated dabigatran (adjusted HR \[aHR\]: 0.84, 95% confidence interval \[CI\]: 0.80--0.87), rivaroxaban (aHR: 0.70, 95% CI: 0.68--0.73, P\<0.001), or apixaban (aHR: 0.57, 95% CI: 0.55--0.60, P\<0.001) were 16%, 30%, and 43% less likely to discontinue treatment, respectively.

When *compared to apixaban*, patients who initiated warfarin (aHR: 1.74, 95% CI: 1.67--1.82, P\<0.001), dabigatran (aHR: 1.46, 95% CI: 1.38--1.54, P\<0.001), and rivaroxaban (aHR: 1.23, 95% CI: 1.17--1.28, P\<0.001) were significantly more likely to discontinue treatment, after adjusting for baseline characteristics ([Table 2](#pone.0195950.t002){ref-type="table"} and [Fig 3](#pone.0195950.g003){ref-type="fig"}).

10.1371/journal.pone.0195950.t002

###### Adjusted hazard ratios of discontinuation.

![](pone.0195950.t002){#pone.0195950.t002g}

  ----------------------------------------------------------------------------- ------------------------------------------------------- ---------------------------------------- ------------- ------------------------------------------------------- ---------------------------------------- ------------- ------ ---------
                                                                                **Hazard Ratio**[\*](#t002fn001){ref-type="table-fn"}   **Hazard Ratio 95% Confidence Limits**   **P-value**   **Hazard Ratio**[\*](#t002fn001){ref-type="table-fn"}   **Hazard Ratio 95% Confidence Limits**   **P-value**          
  Warfarin                                                                      1.74                                                    1.67                                     1.82          \<0.001                                                 1.00 Reference                                                
  Dabigatran                                                                    1.46                                                    1.38                                     1.54          \<0.001                                                 0.84                                     0.80          0.87   \<0.001
  Rivaroxaban                                                                   1.23                                                    1.17                                     1.28          \<0.001                                                 0.70                                     0.68          0.73   \<0.001
  Apixaban                                                                      1.00 Reference                                                                                                                                                         0.57                                     0.55          0.60   \<0.001
  *Covariates Included in Both Models Have the Same Estimates as Shown Below*                                                                                                                                                                                                                                        
                                                                                **Hazard Ratio**[\*](#t002fn001){ref-type="table-fn"}   **Hazard Ratio 95% Confidence Limits**   **P-value**                                                                                                                         
  Age (75+ as a reference category)                                                                                                                                                                                                                                                                                  
  18--64                                                                        1.34                                                    1.30                                     1.38          \<0.001                                                                                                               
  65--74                                                                        0.99                                                    0.96                                     1.03          0.554                                                                                                                 
  Male                                                                          1.02                                                    0.99                                     1.05          0.226                                                                                                                 
  Embolic or Primary Ischemic Stroke                                            0.96                                                    0.88                                     1.05          0.394                                                                                                                 
  Dyspepsia or Stomach Discomfort                                               1.10                                                    1.06                                     1.14          \<0.001                                                                                                               
  Congestive Heart Failure                                                      0.96                                                    0.93                                     0.99          0.007                                                                                                                 
  Coronary Artery Disease                                                       1.01                                                    0.98                                     1.04          0.557                                                                                                                 
  Diabetes                                                                      0.89                                                    0.87                                     0.92          \<0.001                                                                                                               
  Hypertension                                                                  0.89                                                    0.86                                     0.91          \<0.001                                                                                                               
  Renal Disease                                                                 1.04                                                    0.99                                     1.08          0.116                                                                                                                 
  Myocardial Infarction                                                         1.05                                                    0.99                                     1.11          0.093                                                                                                                 
  History of Stroke or Transient Ischemic Attack                                0.85                                                    0.79                                     0.92          \<0.001                                                                                                               
  History of Bleeding                                                           1.12                                                    1.08                                     1.16          \<0.001                                                                                                               
  ----------------------------------------------------------------------------- ------------------------------------------------------- ---------------------------------------- ------------- ------------------------------------------------------- ---------------------------------------- ------------- ------ ---------

\*Adjusted hazard ratios were estimated from a Cox proportional hazards model with factors for age, sex, embolic or primary ischemic stroke, dyspepsia or stomach discomfort, congestive heart failure, coronary artery disease, diabetes, hypertension, renal disease, myocardial infarction, history of stroke or transient ischemic attack, and history of bleeding.

For sensitivity analysis, discontinuation was assessed among patients with at least 100 days of follow-up, given the varied mean follow-up length across treatment cohorts in the main analysis. This reduced the effective sample size to 13,294 patients (35.50%) initiating warfarin, 5,353 (14.29%) apixaban, 4,161 (11.11%) dabigatran, and 14,644 (39.10%) rivaroxaban.

When *compared to warfarin*, patients who initiated dabigatran (aHR: 0.89, 95% CI: 0.85--0.92, P\<0.001), rivaroxaban (aHR: 0.72, 95% CI: 0.70--0.74, P\<0.001), or apixaban (aHR: 0.61, 95% CI: 0.58--0.64, P\<0.001) were less likely to discontinue treatment ([S3](#pone.0195950.s006){ref-type="supplementary-material"} and [S4](#pone.0195950.s007){ref-type="supplementary-material"} Tables and [Fig 3](#pone.0195950.g003){ref-type="fig"}). When *compared to apixaban*, patients who initiated warfarin (aHR: 1.64, 95% CI: 1.57--1.71, P\<0.001), dabigatran (aHR: 1.45, 95% CI: 1.37--1.53, P\<0.001), or rivaroxaban (aHR: 1.18, 95% CI: 1.12--1.23, P\<0.001) were more likely to discontinue treatment ([S1](#pone.0195950.s004){ref-type="supplementary-material"} and [S3](#pone.0195950.s006){ref-type="supplementary-material"} Tables; [Fig 1](#pone.0195950.g001){ref-type="fig"}).

Discussion {#sec004}
==========

When compared to those who initiated warfarin, patients who initiated dabigatran, rivaroxaban, or apixaban were less likely to discontinue treatment after adjusting for baseline characteristics. Further, when compared to apixaban, patients who initiated treatment with warfarin, dabigatran, or rivaroxaban were more likely to discontinue treatment.

This study used real-world claims data from the US population to provide critical insights regarding the risk of discontinuation in an adult NVAF population who initiated anticoagulant treatment with apixaban, warfarin, rivaroxaban, or dabigatran therapy. Importantly, these 'real-world' results are consistent with the clinical trial findings for the respective NOACs and warfarin. In the ARISTOTLE trial, for example, fewer patients in the apixaban group (25.3%) compared to the warfarin group (27.5%) discontinued the study drug before the end of the study (p = 0.001) \[[@pone.0195950.ref006]\]. In the ROCKET-AF trial, the proportion of patients who permanently stopped their assigned therapy before an end-point event and before the termination date was 23.7% in the rivaroxaban group and 22.2% in the warfarin group \[[@pone.0195950.ref005]\]. In the RE-LY trial, the rates of discontinuation for 110 mg of dabigatran, 150 mg of dabigatran, and warfarin were 14.5%, 15.5%, and 10.2%, respectively, at 1 year and 20.7%, 21.2%, and 16.6%, respectively, at 2 years \[[@pone.0195950.ref004]\].

The robustness of these findings through sensitivity analysis was also assessed, which largely concurred with our primary findings by demonstrating a lower risk of discontinuation with NOAC initiation as compared to warfarin, and a higher risk of discontinuation with initiation on other anticoagulants as compared to apixaban.

Our results also confirm findings from recent 'real-world' studies. A long-term study of the different NOACs in clinical practice showed that discontinuation rates were lower for apixaban (10%) compared to dabigatran (30%) and rivaroxaban (25%; p\<0.001 for both) \[[@pone.0195950.ref015]\]. Another study of NVAF patients who initiated oral anticoagulants showed significantly higher 1-year persistence rates with apixaban (86%) and warfarin (85%) than with dabigatran (74%) or rivaroxaban (77%) \[[@pone.0195950.ref016]\]. Furthermore, in a propensity score-matched analysis, patients who initiated dabigatran (63%) had higher persistence rates at 1 year compared to patients who initiated warfarin (39%) \[[@pone.0195950.ref012]\].

Discontinuation of anticoagulation or poor adherence to thromboprophylaxis is not inconsequential. Indeed, previous studies have found that warfarin discontinuation is associated with increased risk of ischemic stroke. For example, Ewen, et al. \[[@pone.0195950.ref017]\] found that patients with 1 or 2 or more warfarin interruptions (defined as prescription gaps over 45 days) had higher stroke incidence than those without warfarin interruption (relative risk: 2.29; 95% CI: 1.29--4.07). Deitelzweig, et al. also found that stroke risk was higher with warfarin discontinuation than during continuous warfarin therapy (HR: 1.60; 95% CI: 1.35--1.90) \[[@pone.0195950.ref018]\]. Similarly, in a study by Spivey et al., discontinuation versus persistent use of warfarin was associated with increased risk of ischemic stroke (HR: 2.04; 95% CI: 1.47--2.84) and ischemic stroke or TIA (HR: 1.50; 95% CI: 1.20--1.87) \[[@pone.0195950.ref019]\].

The anticoagulant effect of NOACs decreases rapidly; therefore, poor adherence and treatment discontinuation may diminish the benefit of NOAC treatment \[[@pone.0195950.ref020]\]. A higher risk of thromboembolism was noted at the end of the double-blind trials during the transition from rivaroxaban to open-label warfarin \[[@pone.0195950.ref021]\]. A recent analysis from the ROCKET-AF trial showed an increased risk of stroke and non-central nervous system embolism among rivaroxaban-treated versus warfarin-treated AF patients who temporarily or permanently discontinued anticoagulation (HR: 1.50, 95% CI: 1.05--2.15) \[[@pone.0195950.ref021]\]. Furthermore, a longitudinal outcomes study using a national cohort from the Veterans Health Administration showed that lower adherence to dabigatran was associated with an increased risk of combined all-cause mortality and stroke (HR: 1.13, 95% CI: 1.07--1.19 per 10% decrease in proportion of days covered) \[[@pone.0195950.ref022]\]. However, several 'real-world' studies have demonstrated reduced or similar ischemic stroke risk among patients treated with NOACs compared with warfarin, suggesting adequate adherence to maintain the benefits of NOACs \[[@pone.0195950.ref020]\].

Our results are also consistent with indirect comparisons that combined data from the RELY, ROCKET-AF, and ARISTOTLE studies in relation to the discontinuation of treatment \[[@pone.0195950.ref023]\]. While the reasons for discontinuation, causality between any particular attribute, and discontinuation of therapy cannot be determined in this retrospective study, the safety and tolerability profile of a drug likely plays a critical role in patients' ability to use NOACs continuously. For example, a 2012 study showed the rate of discontinuation of dabigatran was 25.4%, with dyspepsia being the most common reason for discontinuation \[[@pone.0195950.ref024]\]. Further, a single clinical center cross-sectional study in the United States reported that the most common reasons for discontinuation with dabigatran were adverse reactions and cost \[[@pone.0195950.ref025]\].

The study's strengths are that we assessed the real-world risk of discontinuation of treatment among patients initiating warfarin versus dabigatran, rivaroxaban, and apixaban using the comprehensive MarketScan^®^ claims database, which incorporates all medical and pharmacy patient claims and allows for longitudinal analysis of a nationally-representative sample. The medications being studied are relatively new to the market, and this database, encompassing both commercial and Medicare beneficiaries, allows for the selection of a nationally-representative sample for this study \[[@pone.0195950.ref013]\].

As with any retrospective analysis, researchers are limited to only study associations between variables; additionally, as with any retrospective observational database study, there is a potential for selection bias. We conducted rigorous and thorough multivariate and sensitivity analyses for discontinuation to ensure the robustness of our findings. Baseline comorbidities (eg, presence of renal impairment) were determined by the presence of a diagnosis code in the baseline period and were not based on actual laboratory test result values or clinical assessment. As this study is an analysis of claims data, there is the potential for coding errors or missing data (ie, we must assume that patients do not have a condition if it was not coded). Additionally, refill data may not reflect actual medication use. Discontinuation rates of warfarin, as assessed by a 30-day gap in pharmacy claims, may vary more due to dose adjustments to manage fluctuation in INR values compared to NOACs. As apixaban had entered the market recently when the analysis was performed, patients treated with apixaban tended to have a shorter follow-up than those treated with warfarin.

Further analyses using propensity-matched cohorts as well as large-scale prospective studies may be necessary to understand the reasons for and predictors of discontinuation, and to examine the impact of discontinuation on clinical outcomes.

Conclusions {#sec005}
===========

Among newly-anticoagulated AF patients in the real-world setting, treatment initiation with rivaroxaban, dabigatran, or apixaban was associated with a significantly lower risk of discontinuation as compared to warfarin. Treatment discontinuation risk was significantly higher among patients initiating dabigatran, rivaroxaban, or warfarin, as compared to those initiating apixaban.
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